Halozyme Therapeutics, Inc. $HALO Shares Bought by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 640.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,512 shares of the biopharmaceutical company’s stock after buying an additional 21,202 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Halozyme Therapeutics were worth $2,706,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. Congress Asset Management Co. lifted its holdings in Halozyme Therapeutics by 85.6% in the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock worth $251,890,000 after purchasing an additional 1,052,509 shares during the period. Bank of America Corp DE acquired a new stake in Halozyme Therapeutics during the 2nd quarter worth about $214,504,000. William Blair Investment Management LLC purchased a new position in Halozyme Therapeutics during the 2nd quarter valued at about $196,540,000. Royal London Asset Management Ltd. grew its stake in Halozyme Therapeutics by 12.4% during the 2nd quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock valued at $141,732,000 after acquiring an additional 200,262 shares in the last quarter. Finally, Jupiter Topco LLC acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $105,570,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

HALO has been the subject of several research analyst reports. Citizens Jmp boosted their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research report on Friday, August 7th. Stifel Nicolaus set a $130.00 target price on Halozyme Therapeutics in a research note on Friday, October 16th. TD Cowen lifted their price target on Halozyme Therapeutics from $105.00 to $130.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, August 31st. Finally, Zacks Research raised Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $99.55.

Halozyme Therapeutics Stock Up 0.9%

HALO stock opened at $125.63 on Friday. The stock has a market capitalization of $14.26 billion, a P/E ratio of 37.50, a price-to-earnings-growth ratio of 0.47 and a beta of 0.88. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $126.23. The firm has a 50-day moving average price of $111.37 and a 200-day moving average price of $87.03.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same period in the previous year, the firm posted $1.54 EPS. The firm’s revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 8.31 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $82,482,605.40. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the sale, the director directly owned 40,418 shares of the company’s stock, valued at $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 125,852 shares of company stock worth $13,538,046 in the last 90 days. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.